Beta 3 Agonist Treatment in Heart Failure-2

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 23, 2017

Primary Completion Date

January 21, 2021

Study Completion Date

January 21, 2021

Conditions
Heart Failure With Reduced Ejection Fraction NYHA Class III-IV
Interventions
DRUG

Mirabegron

"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."

Trial Locations (1)

2100

Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Bispebjerg-Frederiksberg Hospital, Denmark

UNKNOWN

collaborator

Hillerød hospital, Denmark

UNKNOWN

collaborator

Herlev Hospital

OTHER

collaborator

Hvidovre University Hospital

OTHER

collaborator

Bornholm Hospital, Denmark

UNKNOWN

collaborator

Royal North Shore Hospital

OTHER

lead

Henning Bundgaard

OTHER

NCT03926754 - Beta 3 Agonist Treatment in Heart Failure-2 | Biotech Hunter | Biotech Hunter